Navigation Links
Prasco® Selected as Eli Lilly and Company's Authorized Generics Partner

CINCINNATI, Oct. 20, 2011 /PRNewswire/ -- Prasco Laboratories, announced today it has signed a marketing and distribution agreement with Eli Lilly and Company (NYSE: LLY) to market the Authorized Generic version of ZYPREXA® (olanzapine) Tablets and ZYPREXA® ZYDIS (olanzapine) Orally Disintegrating Tablets, in the U.S.

Prasco will begin distribution of both products upon the first ANDA entrant into the market.  Prasco will market all six strengths of Olanzapine Tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg.  Olanzapine Orally Disintegrating Tablets will be available in 5 mg, 10 mg, 15 mg, and 20 mg strengths. The financial terms of the agreement were not disclosed.

"Prasco's passion to bring high quality, low cost prescription drugs to consumers continues to expand," said Prasco Chief Executive Officer E. Thomas Arington. "We are especially excited to welcome Eli Lilly and Company to our Prasco family of partners."

Prasco is established as the Authorized Generics company, having brought more Authorized Generics to market than any other company by offering generic products that are identical to the Brand product. "Prasco partnerships with brand companies offer alternatives for consumers and pharmacists that are specific and measurable. This is especially true with the Olanzapine launch through our new Lilly relationship," Arington concluded.  

Olanzapine Tablets are therapeutically equivalent and substitutable for the brand ZYPREXA.  Olanzapine Orally Disintegrating Tablets are therapeutically equivalent and substitutable for the brand ZYPREXA ZYDIS.  

For additional information about ZYPREXA and ZYPREXA ZYDIS, please see Full Prescribing Information including Box Warning at and Medication Guide at

About Prasco Laboratories - Prasco, the Authorized Generics company, is the privately held healthcare company located in Mason, Ohio, that specializes in Authorized Generics. Prasco Authorized Generics provide patients with the identical brand drug experience at a price that competes with generics. Prasco Authorized Generics also simplify interactions between pharmacists and consumers because they are identical to branded drugs. Moreover, Prasco Authorized Generics offer brand pharmaceutical companies a strategic lifecycle management solution.

Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant, VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products and cold-chain distribution. For more information, visit

For additional information about ZYPREXA and/or ZYPREXA ZYDIS, please contact:  Stefanie Prodouz, Manager, Lilly Bio-Medicines Communications | 317.224.5331.

SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prasco® Launches Authorized Generic with Shionogi Inc.
2. Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
3. Prasco Named Exclusive U.S. Distributor for Selected Aspen Branded Products
4. Christine Pierre Selected as "Professional Woman of the Year"
5. Dr. Paul Farmer Selected as 2011 Pro Bono Humanum Honoree by Prix Galien USA
6. Coloplast Selected By LifeScience Alley to Host Minnesota Medical Device Panel
7. BioSurplus Selected to Auction $10 Million in Lab Equipment
8. Linet Multicare® Hospital Bed Selected to Participate in National Program Highlighting Commitment to Healthcare Performance Improvement, Innovation
9. Dr. Jay Yadav, CardioMEMS Founder & CEO, Selected as a Finalist for 2011 Business Person of the Year Award
10. Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China
11. Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker-Selected NSCLC Patients
Post Your Comments:
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... nouvelle approche consistant à combiner l,immunothérapie au traitement ...    --> Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... November 27, 2015 Ein ... fortgeschrittenem Krebs.   --> Ein neuer ... Krebs.   --> Ein neuer ... Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November 2015 ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge ... imaging in the Waterloo region. Using the Ocean Platform, family physicians can now ... their electronic medical record (EMR) without the need for redundant patient entry or ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
Breaking Medicine News(10 mins):